Compare SoFi Technologies Inc (SOFI) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SoFi Technologies Inc vs BIO-TECHNE Corp — how do they compare? SoFi Technologies Inc trades at $17.64 (market cap $21.82B), while BIO-TECHNE Corp trades at $71.63 (market cap $11.16B). The key difference: SoFi Technologies Inc is the larger of the two by market cap, and BIO-TECHNE Corp pays a 0.45% dividend while SoFi Technologies Inc pays none. Which is the better fit depends on your goals.
| SOFI | TECH | |
|---|---|---|
Market Cap | $21.82B | $11.16B |
Sector | Financials | Health |
52-Week High | $32.21 | $72.12 |
52-Week Low | $15.15 | $43.31 |
Enterprise Value | — | $11.24B |
Dividend Yield | — | 0.45% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SoFi Technologies Inc
SoFi is a financial services company that was founded in 2011 and is currently based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020 the company also offers payment and account services for debit cards and digital banking.
Read more on SOFI →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
